India Scrambles to Stem COVID-19 Tide as New Cases Continue to Surge India's response to its new COVID-19 epidemic is going through an inflexion. Passengers at a bus terminal, amid the ongoing surge in coronavirus cases, in Kanpur, Friday, April 16, 2021. Photo: PTI Bengaluru: India’s response to its new COVID-19 epidemic is going through an inflexion. It was most prominent when the government stopped sharing its daily bulletin of adverse events following immunisation. Next, Brazil’s vaccine regulator Anvisa said Bharat Biotech wasn’t following good manufacturing practices to make Covaxin, the ‘Made in India’ vaccine in the country’s two-vaccine inoculation campaign. Supporters of the government rose in its defence but the presence of problems was unmistakable, calling into question why India’s vaccine regulator didn’t notice them.